Intra-cellular Therapies, Inc. (ITCI)

$65.54

-0.83

(-1.25%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Intra-cellular Therapies, Inc.

  • Increasing Revenue

    Revenue is up for the last 17 quarters, 882.51K → 144.86M (in $), with an average increase of 24.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -28.57M → -15.24M (in $), with an average increase of 87.4% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 52.8% return, outperforming this stock by 43.9%

Performance

  • $64.99
    $66.44
    $65.54
    downward going graph

    0.84%

    Downside

    Day's Volatility :2.18%

    Upside

    1.35%

    downward going graph
  • $45.50
    $84.89
    $65.54
    downward going graph

    30.58%

    Downside

    52 Weeks Volatility :46.4%

    Upside

    22.79%

    downward going graph

Returns

PeriodIntra-cellular Therapies, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-8.41%
-1.8%
0.0%
6 Months
9.97%
10.1%
0.0%
1 Year
8.87%
13.2%
0.0%
3 Years
66.9%
17.0%
-21.4%

Highlights

Market Capitalization
7.0B
Book Value
$6.15
Earnings Per Share (EPS)
-1.16
PEG Ratio
0.0
Wall Street Target Price
91.64
Profit Margin
-21.57%
Operating Margin TTM
-14.46%
Return On Assets TTM
-11.23%
Return On Equity TTM
-18.07%
Revenue TTM
513.9M
Revenue Per Share TTM
5.34
Quarterly Revenue Growth YOY
52.0%
Gross Profit TTM
95.2M
EBITDA
-131.4M
Diluted Eps TTM
-1.16
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.53
EPS Estimate Next Year
1.16
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    85%Buy
    15%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Intra-cellular Therapies, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
16
16
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 39.82%

Current $65.54
Target $91.64

Technicals Summary

Sell

Neutral

Buy

Intra-cellular Therapies, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Intra-cellular Therapies, Inc.
Intra-cellular Therapies, Inc.
-10.54%
9.97%
8.87%
66.9%
403.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
2.51%
23.34%
52.82%
44.74%
75.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.83%
-2.78%
1.45%
13.09%
13.09%
Zoetis Inc.
Zoetis Inc.
7.35%
-4.88%
3.24%
-2.99%
66.7%
Viatris Inc.
Viatris Inc.
-10.03%
11.46%
14.27%
-31.33%
-36.29%
Catalent, Inc.
Catalent, Inc.
-1.97%
40.17%
47.68%
-47.44%
21.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Intra-cellular Therapies, Inc.
Intra-cellular Therapies, Inc.
NA
NA
0.0
-0.53
-0.18
-0.11
NA
6.15
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.18
38.18
0.44
4.06
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.2
28.2
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
32.87
32.87
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Intra-cellular Therapies, Inc.
Intra-cellular Therapies, Inc.
Buy
$7.0B
403.38%
NA
-21.57%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.1B
75.5%
38.18
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.6B
13.09%
28.2
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$78.5B
66.7%
32.87
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.5B
-36.29%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$9.9B
21.93%
211.02
-28.44%

Institutional Holdings

  • FMR Inc

    10.85%
  • Vanguard Group Inc

    8.74%
  • BlackRock Inc

    7.76%
  • Wasatch Advisors LP

    3.65%
  • Bellevue Group AG

    2.67%
  • venBio Select Advisor LLC

    2.34%

Corporate Announcements

  • Intra-cellular Therapies, Inc. Earnings

    Intra-cellular Therapies, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Organization
Intra-cellular Therapies, Inc.
Employees
610
CEO
Dr. Sharon Mates Ph.D.
Industry
Health Technology

FAQs